was a derivative of the growth hormone-releasing peptide-1, which is itself derived from the natural protein hormone ghrelin. Ghrelin is often known as the hunger hormone. The stomach produces ghrelin, and its consumption stimulates the intake of food. The cells in the anterior pituitary gland are activated by ghrelin, which increases the levels of growth hormone and neuropeptide Y. Ghrelin is of significant value in learning, reward cognition, memory, energy metabolism, and the sleep-wake cycle.
The ipamorelin prices are so affordable since they can be easily produced via recombinant techniques. It does not retain all the properties of ghrelin which makes it more selective than ghrelin and therefore more useful.
Peptide Sequence: Aib-His-D-2Nal-D-Phe-Lys
Molecular Formula: C38H49N9O5
Molecular Weight: 711.868 g/mol
Working of Ipamorelin
The GHS receptor, also called the ghrelin receptor, is highly expressed in the anterior pituitary gland and hypothalamus. The growth hormone is released from the anterior pituitary gland as the agonists bind to the GHS-R in the pituitary gland. Five most active GHS-R binding amino acids are present in Ipamorelin, making this short peptide the smallest known GHS-R agonist.
The administration of ipamorelin stimulates the release of neuropeptide Y, which leads to an increased appetite, decreased pain perception, and changes in energy metabolism.
The specific receptors required for stimulating the release of neuropeptide Y are situated in the hypothalamus, and the binding to the GHS-R triggers the release of this peptide.
The neuropeptide Y release is associated with the increase in food intake. Therefore, it mainly alters food preferences, thereby increasing the storage of energy as fat and reducing anxiety and stress.
Research has shown the effectiveness of ipamorelin in reducing neuropathic pain, i.e., the pain associated with nerve dysfunction, and reducing visceral pain, i.e., the GI tract and organ pain. In addition, research studies in rats have indicated a reduction in pain perception by as much as 2-fold.
Some research studies in rats have shown the association of ipamorelin with the regulation of bone turnover and promoting increased mineralization of existing bones and the formation of new bones.
Research in rats has shown the effectiveness of ipamorelin, particularly in offsetting the effects of substances like corticosteroids and certain medical conditions known to compromise bone health and increase bone formation by as much as four-fold. In addition, Ipamorelin has been shown to prevent the aberrant fat deposition seen with high corticosteroid levels and prevent bone loss. These findings are appealing as the ability to overcome the side effects of steroid treatment can permit for using higher or long-term doses in chronic inflammatory conditions like cancer and certain autoimmune diseases.
The relationship between ghrelin and heart health is a complicated one. However, the cell culture and the in vivo research in animal models have shown that ghrelin may help protect the heart after a heart attack or other cardiac damages. Furthermore, it is also observed that the ghrelin produced in minute amounts in the vascular system may help in reducing the scar formation and the successive hypertrophy of the heart. This can thereby put a stop to the long-term consequences of heart damage and also heart failure. Therefore, Ipamorelin is an attractive option for researchers since it can be used as a potential therapeutic agent in future applications.
Gender Differences in Ipamorelin Responses
Research studies conducted in mice, rats, and pigs suggest that the peptide shows objectively larger benefits in females than males. The relative lack of testosterone in females compared to males is supposed to be why the peptide’s more effective in females. The lower levels of testosterone are associated with a decrease in muscle anabolism and lower bone mineral density. The research studies are ongoing to confirm any other reasons associated with the higher effectiveness of the peptide in females.
Preeclampsia, a condition in which a pregnant woman experiences potentially dangerous high blood pressure, is one of the primary drivers of preterm delivery and is very dangerous to treat. Research has shown the deficiency of ghrelin in patients affected with early-onset preeclampsia, and the administration of this peptide can promote blood vessel growth and reduce this problem.
Ipamorelin is a highly selective GHS-R agonist and also versatile. It is inexpensive as compared to the other GH secretagogues and GHS-R receptors. The quantity required for an extremely robust research project will cost less than $100 per month, which makes ipamorelin an exceptionally affordable peptide.
Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.